Cannabis Law Report

NOVEMBER 26, 2019

The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.

Safety 64

Safety Food CBD Oil 64

Veriheal

NOVEMBER 18, 2022

According to the Texas Department of Public Safety Chief Wayne Muller, the state has averaged a 10% month-over-month increase in medical cannabis patients over the last 18 months. Back in 2019 , the program was expanded to include ALL individuals with epilepsy—not just those with intractable epilepsy as the program had originally outlined.

Edibles 98

Edibles Hemp Epilepsy Programs 98

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Today (30 May) at 09.30 The organization will focus on the use of special treatment schemes.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Shutterstock). One of the leading cannabis clinicians in the U.S.,

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

MMJ Recs

NOVEMBER 17, 2023

MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more. Seizure Control: For patients with epilepsy and seizure disorders, certain cannabis-based treatments have shown remarkable effectiveness in reducing the frequency and severity of seizures.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Canna Law Blog

NOVEMBER 29, 2019

Epidiolex is used to treat epilepsy and requires a prescription. I don’t doubt that the FDA based its above conclusions regarding Hemp-CBD on some set of studies or other data set, but it’s hard to justify the FDA making these claims without any reference to how the FDA reached these conclusions. Consumer Update. Conclusion.

Hemp 137

Hemp CBD Data Food 137

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 11, 2021

The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

Cannabis Law Report

AUGUST 5, 2019

The two-year experiment is being overseen by the French Agency for Drug Safety (ANSM), which drew up a 13-name committee to explore the possibilities of reform in one of Europe’s largest markets in December 2018. France is searching for patients to take part in an official medical cannabis trial, but users will not be smoking the drug.

Medicine 60

Medicine Patients Digestion Epilepsy 60

Freedom Leaf

OCTOBER 15, 2018

On the basis of their review, the agency approved Epidiolex for use in treating rare forms of childhood epilepsy (Lennox-Gastaut syndrome and Dravet syndrome). Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S. will top $1.9 billion by 2022.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Canna Law Blog

DECEMBER 16, 2021

Psilocybin research license, which will allow the testing potency, conducting clinical investigations, researching efficacy and safety, and agricultural research. Data from the RAND Corporation show that 8,000 New York veterans from the Wars in Iraq and Afghanistan suffer from PTSD.

Legislation 97

Legislation Treatment Therapy Conditions 97

The Joint Blog

MARCH 16, 2020

For the study researchers examined the use of marijuana over a 12-month period in a cohort of patients with chronic diseases, such as HIV, epilepsy, and fibromyalgia. The aim of the study was to assess the psychological safety and QoL of patients with chronic diseases who self-medicate with cannabis over time.

Patients 49

Patients Marijuana Epilepsy Treatment 49

The Joint Blog

JANUARY 23, 2020

. “Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.”

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Cannabis Law Report

MAY 10, 2019

Use of vape oil reduces the risk of side effects of epilepsy and treats any complications linked to epilepsy-like psychiatric disease, neurodegeneration and neuronal injury. There is a lack of safety data availability. Using these oils reduces symptoms like anxiety, mood-related symptoms, insomnia and pain.

Vaping 45

Vaping Oil CBD Epilepsy 45

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA considers delta-8 THC to pose serious health and safety risks. Many CBD users have reported improvements in: Stress; Anxiety; Sleep; Pain levels; Skin conditions including acne and eczema; Epilepsy”. In particular, FDA highlighted the following –. Moving Forward.

THC 52

THC CBD Food Pets 52

The Joint Blog

JANUARY 12, 2020

Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness. Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Veriheal

AUGUST 31, 2020

Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Essay: “Crowdsourcing User Experience Data for a Targeted Medical Cannabis Journey with Cannamunity” . School: Tufts University.

Research and Development 117

Research and Development Education Agriculture Patients 117

Canna Law Blog

JUNE 5, 2019

The objective of the meeting was to gather scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of these products. Others stressed the need to adopt terminology, manufacturing and standards for these products in order to protect the consumer and avoid a public health crisis.

CBD 54

CBD Hemp Food Agriculture 54

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g.,

CBD 40

CBD Research and Development Safety Therapy 40

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

FEBRUARY 15, 2019

There is even published research, derived from clinical trials, on the potential uses of cannabinoids to manage seizures and epilepsy, cited the ministries. As such, the lack of scientific evidence of the safety and efficacy of raw cannabis use supports their position that cannabis should remain an illicit drug.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Otherside Farms

FEBRUARY 14, 2019

billion by 2020; the World Anti-Doping Agency eliminated the CBD from its list of banned substances; The Food and Drug Administration (FDA) for the first time approved a drug for epilepsy that contained CBD oil, prompting the US Drug Enforcement Administration to change its position about the CBD. billion dollars by 2022, with 1.3

CBD 65

CBD Legalization Hemp Chronic Pain 65

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

The Joint Blog

JULY 14, 2021

There has been inadequate research conducted and not enough data that fully supports the use of CBD for the elderly. Older people with underlying conditions such as kidney disease, liver disease, epilepsy, weak immune system, and heart issues should mention it to the doctor before using CBD. The dangers of CBD Products to the Elderly.

Medicine 52

Medicine CBD Chronic Pain Blood Pressure 52

CannaMD

AUGUST 19, 2020

Unlike THC, CBD has a high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity. Our initial data suggest that some C.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy. Cautionary Note on Forward-Looking Statements.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Epilepsy Behav. Consumers spent roughly $31.3 increase in annual sales.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 26, 2021

an organization that provides support to pharmaceutical and biotech companies in North America, Europe, Japan, India and Africa on issues such as product safety, pharmacovigilance, medical devices, clinical trials and regulatory issues. 1 Data published by Research and Markets, March 2018. MyMD: Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 26, 2019

The HSE will establish and maintain a Register for the Medical Cannabis Access Programme to facilitate the enrolment and recording of certain data including patient identifiers (in anonymised format), prescribers enrolled in the programme, as well as prescribed / supplied medical cannabis products.

Medicine 55

Medicine Access Business Legislation 55

CannaMD

SEPTEMBER 15, 2020

Patients suffering from cancer, epilepsy, chronic seizures, or muscle spasms could use low-THC cannabis products recommended by a licensed doctor. To learn more about telehealth appointments and CannaMD ‘s COVID-19 safety measures, see: Coronavirus Policies. Have permanent or temporary residency in the state of Florida.

Law 126

Law Marijuana Patients Treatment 126

Cannabis Info

JULY 12, 2019

CBD for Pets Yes the Data says it works ! Lets review some data. Since then, numerous studies have provided lots of clinical data that CBD can help manage a wide variety of tremors, spasms, and tics. Several months ago, there was a thunder and lightning storm and my dog, Jing, went under the bed for safety as fast as she could….She

Pets 45

Pets Data CBD Cannabinoids 45

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 20, 2021

Data To Support Regulatory Filings in the United States. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. First Patient Expected to be Enrolled by Q2 of 2022.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52